Treatment of Adult Primary Alveolar Proteinosis

被引:8
作者
Rodriguez Portal, Jose Antonio [1 ,2 ]
机构
[1] Inst Salud Carlos III, UMQER Ctr Invest Red Enfermedades Resp CIBERES, Madrid, Spain
[2] Univ Seville, CSIC, Inst Biomed Sevilla IBIS, Hosp Univ Virgen del Rocio Virgen Macarena, Seville, Spain
来源
ARCHIVOS DE BRONCONEUMOLOGIA | 2015年 / 51卷 / 07期
关键词
Pulmonary alveolar proteinosis; Rare diseases; Treatment; Granulocyte colony-stimulating factor-macrophage; COLONY-STIMULATING FACTOR; WHOLE-LUNG LAVAGE; OPEN-LABEL TRIAL; GM-CSF; RITUXIMAB THERAPY; SP-B; MUTATION; TRANSPLANTATION; EFFICACY; PATIENT;
D O I
10.1016/j.arbres.2015.02.003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the accumulation of surfactant-like lipoproteinaceous material in the distal air spaces and terminal bronchi, which may lead to impaired gas exchange. This accumulation of surfactant is due to decreased clearance by the alveolar macrophages. Its primary, most common form, is currently considered an autoimmune disease. Better knowledge of the causes of PAP have led to the emergence of alternatives to whole lung lavage, although this is still considered the treatment of choice. Most studies are case series, often with limited patient numbers, so the level of evidence is low. Since the severity of presentation and clinical course are variable, not all patients will require treatment. Due to the low level of evidence, some objective criteria based on expert opinion have been arbitrarily proposed in an attempt to define in which patients it is best to initiate treatment. (C) 2014 SEPAR. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:344 / 349
页数:6
相关论文
共 48 条
[1]   Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis [J].
Amital, Anat ;
Dux, Shlomo ;
Shitrit, David ;
Shpilberg, Ofer ;
Kramer, Mordechai R. .
THORAX, 2010, 65 (11) :1025-1026
[2]   Autoimmune pulmonary alveolar proteinosis: Clinical course and diagnostic criteria [J].
Ben-Dov, Issahar ;
Segel, Michael J. .
AUTOIMMUNITY REVIEWS, 2014, 13 (4-5) :513-517
[3]  
Bonella F., 2014, Pneumologia, V63, P147
[4]   Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis [J].
Bonfield, TL ;
Kavuru, MS ;
Thomassen, MJ .
CLINICAL IMMUNOLOGY, 2002, 105 (03) :342-350
[5]   Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis [J].
Bonfield, TL ;
Russell, D ;
Burgess, S ;
Malur, A ;
Kavuru, MS ;
Thomassen, MJ .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 27 (04) :481-486
[6]   Rituximab therapy in autoimmune pulmonary alveolar proteinosis [J].
Borie, R. ;
Debray, M-P. ;
Laine, C. ;
Aubier, M. ;
Crestani, B. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (06) :1503-1506
[7]   The molecular basis of pulmonary alveolar proteinosis [J].
Carey, Brenna ;
Trapnell, Bruce C. .
CLINICAL IMMUNOLOGY, 2010, 135 (02) :223-235
[8]  
Chaulagain Chakra P, 2014, Hematol Oncol Stem Cell Ther, V7, P127, DOI 10.1016/j.hemonc.2014.09.003
[9]  
Garber B, 2015, LUNG
[10]   Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis [J].
Happle, Christine ;
Lachmann, Nico ;
Skuljec, Jelena ;
Wetzke, Martin ;
Ackermann, Mania ;
Brennig, Sebastian ;
Mucci, Adele ;
Jirmo, Adan Chari ;
Groos, Stephanie ;
Mirenska, Anja ;
Hennig, Christina ;
Rodt, Thomas ;
Bankstahl, Jens P. ;
Schwerk, Nicolaus ;
Moritz, Thomas ;
Hansen, Gesine .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (250)